Joel S. Marcus, Director at Intra-Cellular Therapies, Inc. (ITCI), sold 20,000 shares at $52.25 ($1.1M) on 2022-03-08, disclosed to the SEC on 2022-03-09.
Open-market sale of $1.1M ITCI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.52 | 5,000 | $273K | 25.7% |
| 2 | $52.25 | 5,000 | $261K | 24.6% |
| 3 | $52.89 | 10,000 | $529K | 49.8% |
| Total | $53.14 avg | 20,000 | $1.1M | 100% |
| Filing → |
| ARE | BUY | 2026-05-07 | $348K | — | Filing → |
| ARE | BUY | 2026-05-06 | $320K | — | Filing → |
| ARE | BUY | 2026-05-05 | $410K | — | Filing → |